Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Rheumatic Disease ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.J Rheumatol. 2004; 31: 390-392
- Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease.Arthritis Rheum. 2005; 52: 826-832
- Profiling anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis.Pediatr Rheumatol Online J. 2012; 10: 29
- Patients with juvenile psoriatic arthritis comprise two distinct populations.Arthritis Rheum. 2006; 54: 3564-3572
- Spondyloarthritis in a pediatric population: risk factors for sacroiliitis.J Rheumatol. 2010; 37: 2402-2408
- Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment.Genes Immun. 2012; 13: 289-298
- Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR).J Rheumatol. 2008; 35: 343-348
- Preliminary definition of improvement in juvenile arthritis.Arthritis Rheum. 1997; 40: 1202-1209
- Are withdrawal trials in paediatric rheumatic disease helpful?.Lancet. 2008; 372: 348-350
- 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features.Arthritis Care Res (Hoboken). 2011; 63: 465-482
- NSAIDs and radiographic progression in ankylosing spondylitis. Bagging big game with small arms?.Ann Rheum Dis. 2012; 71: 1593-1595
- Intra-articular corticosteroids in the treatment of juvenile idiopathic arthritis: safety, efficacy, and features affecting outcome. A comprehensive review of the literature.Open Access Rheumatol Res Rev. 2009; 1: 37-49
- Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial.Rheumatology (Oxford). 2004; 43: 1288-1291
- Risk factors for temporomandibular joint arthritis in children with juvenile idiopathic arthritis.J Rheumatol. 2012; 39: 1880-1887
- Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry.J Rheumatol. 2012; 39: 1867-1874
- Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis.BMC Pediatr. 2012; 12: 29
- Comparative tolerability of treatments for juvenile idiopathic arthritis.BioDrugs. 2000; 14: 159-183
- Sulfasalazine for the management of juvenile rheumatoid arthritis.J Rheumatol. 2001; 28: 845-853
- Leflunomide or methotrexate for juvenile rheumatoid arthritis.N Engl J Med. 2005; 352: 1655-1666
- Leflunomide: a review of its use in active rheumatoid arthritis.Drugs. 1999; 58: 1137-1164
- Etanercept treatment in juvenile idiopathic arthritis: the Polish registry.Med Sci Monit. 2011; 17: SR35-SR42
- Experiences with tumour necrosis factor-{alpha} inhibitors in patients with juvenile idiopathic arthritis: Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry.Rheumatology (Oxford). 2011; 50: 1337-1340
- Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.Ann Rheum Dis. 2009; 68: 635-641
- Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis.Arthritis Rheum. 2009; 60: 2794-2804
- Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.N Engl J Med. 2000; 342: 763-769
- A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis.Arthritis Rheum. 2005; 53: 18-23
- A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.Arthritis Rheum. 2007; 56: 3096-3106
- Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.Lancet. 2008; 372: 383-391
- Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.N Engl J Med. 2008; 359: 810-820
- Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.Lancet. 2008; 371: 998-1006
- Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study.Clin Rheumatol. 2009; 28: 129-137
- A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial).Ann Rheum Dis. 2011; 70: 747-754
- Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial.Ann Rheum Dis. 2011; 70: 1605-1612
- Double blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement.Arthritis Res Ther. 2012; 14: R230
- Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis.Arthritis Rheum. 2012; 64: 2012-2021
- Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.N Engl J Med. 2012; 367: 2385-2395
- Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.N Engl J Med. 2012; 367: 2396-2406
- The German etanercept registry for treatment of juvenile idiopathic arthritis.Ann Rheum Dis. 2004; 63: 1638-1644
- Efficacy of safety of tocilizumab in patients with polyarticular juvenile idiopathic arthritis: data from a phase 3 trial.Arthritis Rheum. 2012; 64 ([abstract]): S682
- Biological therapies: a novel approach to the treatment of autoimmune disease.Am J Med. 1995; 99: 82-88
- Biological therapies for the treatment of juvenile idiopathic arthritis: lessons from the adult and pediatric experiences.Biologics. 2008; 2: 229-252
- Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients.Rheumatology (Oxford). 2011; 50: 189-195
- Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.Arthritis Rheum. 2003; 48: 1093-1101
- Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey.J Rheumatol. 2007; 34: 1146-1150
- Patient outcomes after anti TNF-alpha drugs for Crohn's disease.Expert Rev Pharmacoecon Outcomes Res. 2010; 10: 163-175
- Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.Ann Rheum Dis. 2009; 68: 519-525
- Safety and efficacy of adalimumab treatment in Greek children with juvenile idiopathic arthritis.Scand J Rheumatol. 2011; 40: 101-107
- High dose infliximab in the treatment of refractory uveitis: does dose matter?.ISRN Rheumatol. 2012; 2012: 765380
Tambralli A, Beukelman T, Weiser P, et al. High doses of infliximab in the management of juvenile idiopathic arthritis. J Rheumatol, in press.
- Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy.Arthritis Rheum. 2005; 52: 2103-2108
- Psoriatic juvenile idiopathic arthritis: a tale of two subgroups.Curr Opin Rheumatol. 2011; 23: 437-443
- Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration.Arthritis Rheum. 2010; 62: 2517-2524
- Guilt by association—what is the true risk of malignancy in children treated with etanercept for JIA?.Pediatr Rheumatol Online J. 2010; 8: 23
- Rates of malignancy associated with juvenile idiopathic arthritis and its treatment.Arthritis Rheum. 2012; 64: 1263-1271
- Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment.Arthritis Rheum. 2012; 64: 2773-2780
- Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.Nat Rev Drug Discov. 2012; 11: 633-652
- Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series.Arthritis Rheum. 2011; 63: 545-555
- Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series.J Rheumatol. 2011; 38: 180-181
- Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients.Rheumatology (Oxford). 2011; 50: 417-419
- Anakinra for rheumatoid arthritis.Cochrane Database Syst Rev. 2009; (CD005121)
- A signal achievement in the treatment of arthritis.Arthritis Rheum. 2005; 52: 2229-2232
- Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis.Graefes Arch Clin Exp Ophthalmol. 2011; 249: 297-300
- Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment.Arthritis Res Ther. 2010; 12: R67
- Adverse effects of biologics: a network meta-analysis and Cochrane overview.Cochrane Database Syst Rev. 2011; (CD008794)
- Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases.Biol Pharm Bull. 2007; 30: 2001-2006
- Radiographic improvement of damaged large joints in children with systemic juvenile idiopathic arthritis following tocilizumab treatment.Ann Rheum Dis. 2011; 70: 1693-1695
- Overview of safety of non-biologic and biologic DMARDs.Rheumatology (Oxford). 2012; 51: vi37-vi43
- Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement.Arthritis Res Ther. 2005; 7: R1281-R1288
- Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.Semin Oncol. 1999; 26: 66-73
- Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis.Clin Rheumatol. 2011; 30: 1163-1172
- Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab).Rheumatology (Oxford). 2011; 50: 1390-1394
- Tolerability and safety of rituximab (MabThera).Cancer Treat Rev. 2005; 31: 456-473
- Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies.Arthritis Rheum. 2012; 64: 3043-3051
- Non-infectious pulmonary toxicity of rituximab: a systematic review.Rheumatology (Oxford). 2012; 51: 653-662
- Systemic onset juvenile rheumatoid arthritis.Baillieres Clin Rheumatol. 1998; 12: 245-271
Article info
Publication history
Published online: July 08, 2013
Footnotes
Disclosures: None.
Identification
Copyright
© 2013 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
